These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 31088326)

  • 1. Clinical value of fecal calprotectin.
    Ricciuto A; Griffiths AM
    Crit Rev Clin Lab Sci; 2019 Aug; 56(5):307-320. PubMed ID: 31088326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Both fecal calprotectin and fecal immunochemical tests are useful in children with inflammatory bowel disease.
    Shimizu H; Ebana R; Kudo T; Sato T; Hara T; Hosoi K; Usami M; Yoshida M; Takeuchi I; Nakase H; Iwama I; Arai K; Shimizu T
    J Gastroenterol; 2022 May; 57(5):344-356. PubMed ID: 35165800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children.
    Sidler MA; Leach ST; Day AS
    Inflamm Bowel Dis; 2008 Mar; 14(3):359-66. PubMed ID: 18050298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Fecal calprotectin as a biomarker effectiveness of various interventions in patients with inflammatory bowel disease].
    Lazebnik LB; Guseĭn-Zade MG; Efremov LI; Sagynbaeva VÉ; Kniazev OV
    Eksp Klin Gastroenterol; 2013; (8):11-6. PubMed ID: 24933942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
    D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
    Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pomegranate juice to reduce fecal calprotectin levels in inflammatory bowel disease patients with a high risk of clinical relapse: Study protocol for a randomized controlled trial.
    Scaioli E; Belluzzi A; Ricciardiello L; Del Rio D; Rotondo E; Mena P; Derlindati E; Danesi F
    Trials; 2019 Jun; 20(1):327. PubMed ID: 31171016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
    Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
    Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease.
    Sipponen T; Kolho KL
    Scand J Gastroenterol; 2015 Jan; 50(1):74-80. PubMed ID: 25523558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fecal Calprotectin in Gastrointestinal Disease.
    Murray J; Kok KB; Ayling RM
    Clin Chem; 2023 Jul; 69(7):699-710. PubMed ID: 37228058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noninvasive Fecal Immunochemical Testing and Fecal Calprotectin Predict Mucosal Healing in Inflammatory Bowel Disease: A Prospective Cohort Study.
    Ma C; Lumb R; Walker EV; Foshaug RR; Dang TT; Verma S; Huang VW; Kroeker KI; Wong K; Dieleman LA; Fedorak RN; Halloran BP
    Inflamm Bowel Dis; 2017 Sep; 23(9):1643-1649. PubMed ID: 28644184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calprotectin or Lactoferrin: Do They Help.
    Wright EK
    Dig Dis; 2016; 34(1-2):98-104. PubMed ID: 26982329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostics and prognostics of inflammatory bowel disease with fecal neutrophil-derived biomarkers calprotectin and lactoferrin.
    Sipponen T
    Dig Dis; 2013; 31(3-4):336-44. PubMed ID: 24246984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surrogate Fecal Biomarkers in Inflammatory Bowel Disease: Rivals or Complementary Tools of Fecal Calprotectin?
    Di Ruscio M; Vernia F; Ciccone A; Frieri G; Latella G
    Inflamm Bowel Dis; 2017 Dec; 24(1):78-92. PubMed ID: 29272479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases.
    Dulai PS; Peyrin-Biroulet L; Danese S; Sands BE; Dignass A; Turner D; Mantzaris G; Schölmerich J; Mary JY; Reinisch W; Sandborn WJ
    Gastroenterology; 2019 Oct; 157(4):1032-1043.e1. PubMed ID: 31228441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of faecal calprotectin analysis in adult inflammatory bowel disease.
    Smith LA; Gaya DR
    World J Gastroenterol; 2012 Dec; 18(46):6782-9. PubMed ID: 23239916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fecal Calprotectin.
    Ayling RM; Kok K
    Adv Clin Chem; 2018; 87():161-190. PubMed ID: 30342711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Fecal Calprotectin in Inflammatory Bowel Disease].
    Lee J
    Korean J Gastroenterol; 2016 May; 67(5):233-7. PubMed ID: 27206433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excluding inflammatory bowel disease in the irritable bowel syndrome patient: how far to go?
    Nemakayala DR; Cash BD
    Curr Opin Gastroenterol; 2019 Jan; 35(1):58-62. PubMed ID: 30407259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Fecal calprotectin as a diagnostic marker of inflammatory bowel disease].
    Kostrzewska P; Całkosiński A; Majewski M; Malinowski K
    Pol Merkur Lekarski; 2022 Feb; 50(295):58-61. PubMed ID: 35278302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease.
    Konikoff MR; Denson LA
    Inflamm Bowel Dis; 2006 Jun; 12(6):524-34. PubMed ID: 16775498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.